Dr. Klemen Spaninger

Member of management team responsible for setting company strategy, reporting to suppervisory board. Bioceros, part of Polpharma Biologics, focuses on the development of biosimilar mAbs and recombinant proteins, both for internal programs as well as for clients.

Member of Polpharma biologics management team. Responsible for the overall project management function, providing leadership, coordination, alignment of cross portfolio activities and management of processes and functions. Leading budget and strategic planning for internal biosimilar pipeline. Leading integration process of Bioceros into Polpharma biologics. Reporting to business unit head and senior management. Development of direct reports on leadership and strategic decision making.

MyRISQ team is part of DiaGenomi company. Health is our biggest treasure, therefore our mission is to provide pathology supported genetic testing to patients worldwide and their health care professionals in goal of improving patients quality of life.

Leading cross functional global international teams. Responsible for the management of clinical/ commercial global programs of biosimilar biologics. Have an overview on technical development, TechOps, clinical operations, regulatory, marketing and IP processes. Responsible for strategy planning and reporting to senior management.

20+ employees: Responsible for the co-ordination of all stability samples and four specific biosimilars projects within the DP Analytics team as head of Analytical Laboratories Group at Schaftenau in Austria. Responsible for preparation of STRAT FTE and financial plan for department.

Working on research project focused on molecular mechanisms of cholesterol, lung cancer and erythropoietin.

As a TPL responsible for projects regarding erythropoietin production in Sandoz CMO • Leading global project for restart of erythropoietin production at CMO • Responsible for budget and time lines • Responsible for coordination of QA, QC, RegCMC and TechOps members and activities • Reporting to global steering committee • Involved in preparations of capital appropriation requests (CAR)

Market research, market developement, professional support

Center for Functional Genomics and Bio-Chips (CFGBC) was opened in June 2005. It was established by the Slovenian Consortium for Biochips, the network of Slovenian academic institutions, research institutes, clinical centers and pharmaceutical industry. CFGBC is a part of Institute of Biochemistry, Faculty of Medicine, University of Ljubljana.

Member of A.J. Sytkowski research group. Research focused on erythropoietin and its mutants (R103A). Focus on non-hematopoietic effects of EPO. In vitro testing and lab scale production of EPO mutants.

With a particular emphasis on the leadership, marketing and financial issues faced by growing companies, the program consists of practical monthly training and networking events that enable young entrepreneurs to access the right ideas, knowledge and people.

developing new forms of erythropoietin